Does this delay change how NHS decisions are made?

In short, no.

The decision to delay mergers appears to be driven largely by ongoing devolution discussions and wider local government reorganisation.

Many parts of England are currently reviewing how health, local government and other public services will work together in the future. Until there is greater clarity, creating new ICB structures risks introducing another layer of change to a system that is already adapting.

The strategic direction of travel remains largely unchanged.

Neighbourhood health, place-based care, integrated services and collaboration across larger geographies continue to sit at the heart of NHS planning.

And the challenges facing local healthcare systems remain:

• Financial pressure.
• Workforce shortages.
• Growing demand.
• Variation in care.
• The need to redesign pathways.

These are the issues influencing adoption decisions today, just as they influenced them before Integrated Care Systems existed.

Whether an organisation is called an ICB, a cluster, an alliance or something else in the future, decision-makers will still be asking similar questions:

Does this improve outcomes?

Does this fit within existing pathways?

Can we implement this with the workforce we have?

Does it support local priorities?

What the merger pause really means

Short-term uncertainty around structures may continue.

Leadership responsibilities may evolve.

Geographies may change.

Some systems may operate increasingly through informal collaboration before any formal merger occurs.

The result is that local engagement becomes more important, not less.

Healthcare adoption has always been more local than national.  National policy might shape the direction of travel, but local systems determine the pace.

This remains true regardless of how many ICBs ultimately exist.

Understanding local priorities, pathway challenges, implementation barriers and stakeholder relationships will continue to be critical long after the current merger discussions have been resolved.

A final thought

The story here is not really about mergers. It is about uncertainty.  And uncertainty is increasingly becoming a permanent feature of the NHS landscape.  The organisations most likely to succeed remain those focused on understanding local healthcare needs, building meaningful relationships and supporting implementation in the real world.

Because regardless of what NHS structures look like in 2028, adoption will still happen locally.

How resilient is your access and engagement strategy to NHS organisational change?

At NeoHealthHub, we help clients understand evolving NHS structures, map key stakeholders and develop practical strategies that support adoption at national, regional and local level.

From market access planning to implementation support, contact us to find out how we can we help organisations navigate complexity and deliver real-world results.

The post ICB Merger delays – what does this actually mean? appeared first on NeoHealthHub.

Another NHS reform. Another operating model. Another ambition to move care closer to home, focus on prevention and reduce pressure on hospitals.

Recently, the Chair of NHS England called for an urgent redesign of urgent and emergency care, warning that the current model is not delivering what patients need. The argument itself is familiar. What is more interesting is what sits behind it: an acknowledgement that knowing what needs to change and making change happen are two very different things.

That lesson extends far beyond urgent and emergency care.

The gap between ambition and implementation

A year on from the NHS 10-Year Health Plan, the direction of travel is becoming clear. Prevention, neighbourhood health, integrated care, workforce transformation and digital enablement remain central priorities. Yet implementation remains uneven, with local systems progressing at very different speeds. National frameworks exist, but local readiness varies considerably.

For healthcare companies, this creates a challenge.

Many organisations continue to think about market access as a national exercise. Secure NICE approval, achieve a positive reimbursement outcome and uptake should follow.

The reality is more complex.

Even where national support exists, local funding arrangements, workforce capacity, service design and pathway requirements often determine whether innovation is adopted in practice. National approval may open the door, but local implementation determines whether anyone walks through it.

Why good ideas struggle to become routine care

The challenge facing the NHS is rarely a lack of good ideas.

Most healthcare leaders would agree on the importance of prevention. Few would argue against integrated care, earlier intervention or better management of long-term conditions.

The difficult part is translating these ambitions into everyday clinical practice.

Recent comments from NHS leadership on obesity illustrate this perfectly. The Chair of NHS England highlighted concerns about declining breastfeeding support, arguing that the health service is failing to promote an intervention that could significantly reduce obesity risk. The issue is not that the evidence is unavailable. The issue is turning evidence into consistent implementation across the system.

This pattern repeats itself throughout healthcare, the challenge applies to medicines, diagnostics, digital technologies and healthcare services.

Evidence exists. Guidance exists. Policy exists. Adoption varies.

The local NHS matters more than ever

One of the strongest signals emerging from the NHS 10-Year Health Plan is the increasing importance of neighbourhood and place-based healthcare. Care is gradually shifting away from traditional acute settings towards community-based models, multidisciplinary teams and local partnerships.

For life sciences companies, this changes the commercialisation challenge.

Understanding NICE remains important.

Understanding local systems is becoming essential.

Integrated Care Systems, Primary Care Networks, community providers, finance leads, pathway owners and voluntary sector organisations are playing an increasingly influential role in determining how innovation is adopted. A single national strategy is unlikely to be sufficient in a system where priorities, capabilities and readiness differ significantly between geographies.

The organisations seeing the greatest success are not necessarily those with the strongest national proposition. They are often the ones that understand local barriers, engage the right stakeholders and support implementation after launch.

Commercialisation is no longer just market access

Historically, many organisations viewed market access and commercialisation as separate activities.

Market access focused on reimbursement and approval.

Commercial teams focused on launch and uptake.

Those boundaries are becoming increasingly blurred.

Today’s NHS is looking for solutions that demonstrate clinical value, workforce impact, operational feasibility and financial sustainability simultaneously. Workforce pressures, pathway redesign, digital integration and health inequalities are all influencing decision-making. Products that can demonstrate how they fit into the realities of NHS delivery are more likely to gain traction than those relying on clinical data alone.

This is why commercialisation can no longer begin at launch.

It starts much earlier.

The decisions made during evidence generation, value proposition development, HTA planning and stakeholder engagement often determine how successfully a product is adopted years later.

Approval is only the beginning

The NHS does not have an innovation problem.

It has an implementation challenge.

Whether discussing urgent and emergency care, prevention, digital transformation or medicines adoption, the same question keeps emerging:

How do we move from knowing what should happen to making it happen?

For life sciences organisations, that means looking beyond approval and thinking more broadly about the path to adoption.

• How will local systems implement this?
• Who needs to be engaged?
• What barriers exist today?
• What does success look like in practice?

These are the questions that ultimately determine whether innovation reaches patients.

A final thought

The most successful healthcare innovations are rarely those with the strongest strategy alone.

They are the ones supported by a clear understanding of NHS reality, strong stakeholder engagement and practical implementation planning.

The NHS will continue to evolve. Structures will change. Priorities will shift. The challenge of turning good ideas into routine care will remain.

How prepared is your organisation for the journey from approval to adoption?

NeoHealthHub helps life sciences companies navigate NHS complexity through insight, strategy and implementation support across HTA, launch, adoption and lifecycle optimisation.

Get in touch to discuss how your organisation can accelerate adoption and maximise the value of innovation within the NHS.

The post The NHS Doesn’t Have an Innovation Problem It has an adoption challenge. appeared first on NeoHealthHub.

This report shares unique insights from critical decision makers within the NHS, giving a holistic view of the current state of evolution in the NHS, and an objective view of where to focus support, specifically covering:

• How NHS finances, service provision and structural changes are viewed.
• How manufacturers of pharmaceuticals or Medtech should adapt their value propositions to align with the challenges faced and maximise benefits to services and patients.
• How increased collaboration with industry and third-party partners would support local health systems.

The post Keeping up with the new NHS appeared first on NeoHealthHub.